Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis

ConclusionsIt appears that CGRP mAbs, especially galcanezumab 240  mg, monthly fremanezumab, and eptinezumab 300 mg, seem to be the best choice for the treatment of migraine patients with previous treatment failures. This finding also calls for future research that examine the associations between these medications in migraine therapy among the same patient gr oup to testify the present findings.
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research